Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Michael HerdmanCicely KerrMarco PavesiJamie GarsideAndrew LloydPatricia Cubi-MollaNancy DevlinPublished in: Journal of patient-reported outcomes (2020)
This is the first investigation into the psychometric properties of the FACT-8D. In this RR MCL trial dataset, it showed good convergent validity and responsiveness, but poorer known groups' validity, and EQ-5D performed as well or better on the tests conducted. The FACT-8D may offer an alternative method to generate utilities for the cost-effectiveness analysis of cancer treatments but needs further testing in other types of cancer patients. Evaluation of utility gains may have been limited by high baseline performance status in this RR MCL trial sample.
Keyphrases
- papillary thyroid
- psychometric properties
- squamous cell
- clinical trial
- phase iii
- healthcare
- public health
- acute lymphoblastic leukemia
- phase ii
- acute myeloid leukemia
- mental health
- randomized controlled trial
- squamous cell carcinoma
- multiple myeloma
- lymph node metastasis
- childhood cancer
- hodgkin lymphoma
- social media